<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 4, 2019 (HealthDay News) — A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF<\/i> V600E mutation, according to a study published online Sept. 30 in the New England Journal of Medicine<\/i>. The research was published to coincide with the European Society of Medical Oncology Congress 2019, held from Sept. 27 to Oct. 1 in Barcelona, Spain.<\/p>\n
Scott Kopetz, M.D., Ph.D., from University of Texas M.D. Anderson Cancer Center in Houston, and colleagues randomly assigned 665 patients with BRAF<\/i> V600E-mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators’ choice of either cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil, and irinotecan; control group).<\/p>\n
The researchers found a median overall survival of 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95 percent confidence interval [CI], 0.39 to 0.70; P < 0.001). In the triplet-therapy group, the confirmed response rate was 26 (95 percent CI, 18 to 35) compared with 2 percent (95 percent CI, 0 to 7) in the control group (P < 0.001). In the doublet-therapy group, median overall survival was 8.4 months (hazard ratio for death, 0.60; 95 percent CI, 0.45 to 0.79; P < 0.001) compared with the control group. In the triplet-therapy group, adverse events of at least grade 3 occurred in 58 percent of patients compared with 50 percent in the doublet-therapy group and 61 percent in the control group.<\/p>\n
“This targeted therapy combination should be a new standard of care for this patient group,” Kopetz said in a statement. “Further investigation is needed to determine if this combination may also benefit those with less advanced disease or as a first-line treatment.”<\/p>\n
The study was funded by Array BioPharma.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n